Occult HBV
Occult HBV
Occult HBV
With the introduction of highly sensitive hepatitis B surface antigen immunoassay, transfusion associated HBV
infection have reduced drastically but they still tend to occur due to blood donors with occult hepatitis B infection
(OBI) and window period (WP) infection. Sera from, 24338 healthy voluntary blood donors were screened for
HBsAg, HIV and HCV antibody using Vitros Enhanced Chemiluminescent Immunoassay. The median age of
the donor population was 30 (range 18–54) with male preponderance (98%). All serologically negative samples
were screened by nucleic acid testing (NAT) for viral DNA and RNA. NAT-positive samples were subjected to
discriminatory NAT for HBV, HCV, and HIV and all samples positive for HBV DNA were tested for anti-HBc, anti-
HBs, HBeAg. Viral load was determined using artus HBV RG PCR Kit. Of the 24,338 donors screened, 99.81%
(24292/24338) were HBsAg negative of which NAT was positive for HBV DNA in 0.0205% (5/24292) donors.
Four NAT positive donors had viral load of <200 IU/ml making them true cases of OBI. One NAT positive donor
was negative for all antibodies making it a case of WP infection. Among OBI donors, 75% (3/4) were immune
and all were negative for HBeAg. Precise HBV viral load could not be determined in all (5/5) NAT positive donors
due to viral loads below the detection limit of the artus HBV RG PCR Kit. The overall incidence of OBI and WP
infections was found to be low at 1 in 6503 and 1 in 24214 donations, respectively. More studies are needed to
determine the actual burden of WP infections in Indian blood donors.
Keywords: HBV, Nucleic acid testing, Occult hepatitis B virus infection, Anti-HBc
HBsAg and anti-HBs) has been used as a surrogate marker rule out contamination or false positivity. All repeat reac-
for chronic HBV infection, after reports of HBV infection tive samples by ID-NAT were subjected to discriminatory
following transfusion of such blood and blood components NAT (dNAT) using the Procleix Discrimination test kit
(units).3 This resulted in the implementation of anti-HBc (Chiron, USA) to differentiate between HBV, HCV, and
screening of blood donors with recommendations to dis- HIV nucleic acids. All dNAT HBV DNA positive sam-
card positive units. The major drawback of this policy ples were tested for Anti-HBc, Anti-HBs and HBeAg
was the high discard rates in geographic areas endemic to using Vidas ELFA assays (BioMérieux, Marcy-l’Etoile,
HBV. Window period (WP) HBV infections are classified France). DNA was extracted from 200 μl of plasma using
as pre-anti-HBc or pre-HBsAg WP if all serum markers are QIAamp MinElute Virus Spin kit (Qiagen GmbH, Hilden,
non reactive or, as post-anti-HBc or post-HBsAg WP when Germany) and HBV viral load was determined using CE
IgM anti-HBc is positive coinciding with early recovery marked artus HBV RG PCR Kit (Qiagen GmbH, Hilden,
phase. When HBV DNA is detected in the presence of Germany) in Rotor gene Q. The assay targets 134 bp region
anti-HBs as the sole serological marker, it is classified as of HBV core gene and amplifies all genotypes of Hepatitis
vaccine breakthrough infection or abortive HBV infec- B (A-H). The analytical detection limit of the artus HBV
tion. The factors that determine the length of the WP are RG PCR Kit was 0.02 IU/μl. An internal control DNA
doubling time of viremia and the analytical sensitivity provided in the artus HBV RG PCR Kit was included in
of the screening test. This residual risk has been reduced the isolation procedure. It served as a control for DNA
by implementation of nucleic acid testing (NAT) assay isolation procedure and to check for possible PCR inhibi-
which has shortened the core window period. Previous tion. All PCR reactions included one no template control
Indian studies in anti-HBc positive donors have reported (NTC), a positive control (sample known to contain HBV
a wide range of prevalence of OBI with the lowest of DNA) and internal controls. NTC contained all reagents
0.92% reported from Vellore to as high as 30% reported used in the PCR reaction mixture except the template DNA
from Odisha.4,5 The most plausible reason for such varia- and ensured that the amplification observed in the samples
bility would be the use of assays with varying sensitivity was not due to contamination. Internal control PCR reac-
in different studies for screening the donors as well as the tion ensured that the DNA isolation has worked and there
nature of study population. However, a lone study from are no PCR inhibitors in the sample. Positive control in
Delhi done on all HBsAg negative donors reported a prev- the PCR ensured that the HBV specific amplification was
alence of OBI and WP infections at 0.046 and 0.018%, not hampered. The data were tabulated using MS excel
respectively.6 There is absence of any data on OBI and and analyzed using SPSS v20.
WP infections from the state of Kerala to determine its
incidence among all HBsAg negative blood donors. Results
A total of 24338 donors were tested using serological meth-
Materials and methods ods during the study period and 99.49% (24214/24338)
A cross-sectional study was done on blood donors, who were found negative for all serological markers (HBsAg,
donated to the blood bank from March 2014 to October HIV, HCV, malaria and syphilis). The median age of the
2015. The study was approved by the institutional ethics donor population was 30 (range 18–54) with male pre-
committee. Samples were collected after getting informed ponderance (98%). Of the donors 27 (0.11%) were anti-
consent from the subjects. Serum samples from the donors HIV1/2 positive, 51 (0.21%) were anti-HCV positive and
were tested for HBsAg, HIV and HCV antibody using 46 (0.19%) were HBsAg positive. ID-NAT and dNAT
Vitros Enhanced Chemiluminescent Immunoassay (Ortho- testing of serologically negative samples identified five
Clinical Diagnostics, Raritan, NJ, USA). All negative HBV DNA positive donors of which four were positive
samples were screened, by individual donor nucleic acid for anti-HBc and were classified as true OBI. One donor
testing (ID-NAT) for viral DNA and RNA using Procleix was seronegative (negative for anti-HBc and anti-HBs)
Ultrio Plus kit (Chiron, USA). NAT testing was done in and classified as WP donor. Overall, the prevalence of
batches and with each batch nine calibrators comprising of OBI and WP was found to be 0.017% (4/24214) i.e. 1 in
two positive calibrators for HIV-1, HCV and HBV, respec- 6053 donations and 0.004% i.e. 1 in 24214 donations,
tively and three negative calibrators, were also included. respectively. Among the OBI donors 75% (3/4) were
To enhance the disruption of HBV viral particles, target immune (anti-HBs ≥10 IU/L). All (4/4) OBI cases were
enhancer reagent is used. The internal control included in negative for HBeAg. Of the five HBV DNA positive sam-
the target capture reagent ensures the accurate processing ples, viral load for 60% (3/5), including the case of WP
and amplification of each specimen. Measures to prevent donation, were below the detection limit of the artus HBV
false positive results like the use of magnetic separation RG PCR Kit while in 40% (2/5) cases DNA was detected
and wash steps to remove the extraneous components, but could not be quantified by the artus HBV RG PCR
Selection reagent to inactivate the chemiluminescent Kit due to very low viral load. Therefore, in the absence
label on the unhybridized probes were part of the testing of quantifiable viral load genotyping of HBV could not
protocol. ID-NAT-positive samples were tested again to be carried out.
Discussion
Diagnostics, USA)
Diagnostics, USA)
Diagnostics, USA)
The Netherlands without HBsAg, with or without HBV antibodies, out-
Netherlands
side the acute phase window period.7 Acute phase of HBV
tics, India
infection before the appearance of HBsAg is not considered
Bio-rad
OBI as the patient eventually develops all the markers of
HBV infection.8 Subsequently in 2008,international work-
(Gen-Probe Inc.)
comparable to overt HBV infections due to HBV escape
RG RT-PCR
mutants and are classified as false OBI. Some authors
have classified OBI as seropositive (anti-HBc alone or
together with anti-HBs) or s eronegative (no antibodies).10
The probability of detecting HBV DNA is highest in sub-
Overall prevalence
0.013
0.017
0.05
0.15
0.09
3.9
0.15
Anti-HBc seropositive
7.5
1.1
Table 1 Demographics of published Indian studies on occult hepatitis B virus infection in blood donors
30
1
18.2
60.3
63
–
18.9
30.1
9.19
16.7
8.4
70.43
94.78
98.39
100
98
–
–
–
Vellore/20125
Delhi/200317
Delhi/201224
Delhi/20146*
Delhi/20104
ent study)*
Place/year
studies on OBI were done on anti-HBc positive donors. detected most of the infected cases but the residual risk
Only one recent study from Delhi has actually looked for of transmission of OBI and WP infection still exists. Anti-
OBI in all HBsAg negative donors which detected addi- HBc screening is not an option in Indian setting due to the
tional cases of WP donors.6 Indian studies have reported a high discard rates that it entails and its inability to detect
wide range of OBI prevalence in anti-HBc positive donors WP infections. More studies are needed to determine the
(Table 1). In the year 2010, a study from Delhi reported a actual burden of WP infections in Indian donor population
prevalence of 27.2% among anti-HBc positive donors.17 so as to implement the use of NAT-based screening for all
Incidentally in the same year another study from Delhi HBsAg negative blood donations.
reported a prevalence of only 7.5%.4 Similar studies in
OBI among anti-HBc positive donors from Kolkata and Conflicts of interest
Odisha reported a prevalence of 21.3% and 30%, respec- The authors have no conflicts of interest to declare.
tively (Table 1).18,19 The most recent study from the state
of Tamil Nadu found OBI in only 16.7% of the anti-HBc Ethics approval
positive donors. These high HBV DNA positive rates in The study received ethical approval Amrita Institute of
anti-HBc positive donors reported in various Indian stud- Medical Sciences and Research Center Ethics Committee.
ies is in total disagreement with the low anti-HBc pos-
itivity (6%) reported from studies from highly endemic Funding
countries.20 The reason for such variation in the preva- Cinzia Keechilot was supported by The Indian Council
lence of OBI would be due to the use of HBsAg assay of Medical Research initiated the Short Term Studentship
with varying sensitivity, HBV prevalence and the type of Program for MBBS graduates (Grant No. 2015-01331).
population in which the study was done. Among the five
References
cases that were HBV DNA positive by NAT in our study
1 Puri P. Tackling the Hepatitis B disease burden in India. J Clin Exp
one was a WP donor. The incidence of WP infection in our Hepatol. 2014;4(4):312–319.
study was 1 in 24124 donations which is far less than the 1 2 Allain JP. Occult Hepatitis B virus infection. Hep B Annual.
2005;2:14–30.
in 4689 reported from Delhi and 1 in 5906 reported from 3 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-
China.6,21 High incidence (1 in 1029) of window period core antibody response in the detection of occult Hepatitis B virus
infection. Clin Chem Lab Med. 2010;48:23–29.
donors have been reported from Taiwan.22 Previous studies 4 Asim M, Ali R, Khan LA, Husain SA, Singla R¸ Kar P. Significance
have reported that transmission by window period donors of anti- HBc screening of blood donors and its association with occult
Hepatitis B virus infection: implications for blood transfusion. Indian
was higher (81%) than the occult cases with antibodies J Med Res. 2010;132:312–317.
(19%).13 The remaining four cases were true OBI, with 5 Ismail AM, Devakumar S, Anantharam R, Fletcher GJ, Subramani
three (75%) of them having immune titers (>10 IU/ml) T, John GT, et al. Low frequency of occult hepatitis B infection in
anti-HBc seropositive blood donors: experience from a tertiary care
for anti-HBs which is consistent with reports suggest- centre in South India. Blood Transfus. 2012;10(2):230–232.
ing 90% of anti-HBc positive donors also carry anti- 6 Doda V, Arora S, Kirtania T. Serological characterization of occult
hepatitis B virus infection among blood donors in India. Transfus
HBs thereby indicating recovered infection.13 They also Apher Sci. 2014;51(2):162–167.
found that transmission was independent of HBV DNA 7 Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol.
2004;11:18–25.
load and the presence of anti-HBs (>100 IU/L) offered 8 Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window
some protection.13 It is noteworthy that transmission from period reduction and residual risk. J Clin Virol. 2006;36(Suppl 1):
S23–S29.
donors positive for both anti-HBc and anti-HBs following 9 Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS,
acute hepatitis B has never been documented.11 All our Colombo M, et al. Statements from the Taormina expert meeting
OBI donors were young males which are similar to the on occult hepatitis B virus infection. J Hepatol. 2008;49:652–657.
10 Raimondo G, Pollicino T, Romanò L, Zanetti AR. A 2010 update on
findings from Delhi, where the mean age of OBI cases occult hepatitis B infection. Pathol Biol. 2010;58:254–257, Paris.
was 27.5 years and all were males.6 This is contrary to 11 Hollinger FB. Hepatitis B virus infection and transfusion medicine:
science and the occult. Transfusion. 2008;48:1001–1012.
findings by Candotti et al. where OBI occurred mainly in 12 Chemin I, Trépo C. Clinical impact of occult HBV infections. J Clin
older donors.13 Of the four cases of OBI in our study, artus Virol. 2005;34(Suppl 1):S15–S21.
13 Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus
HBV RG PCR Kit was able to detect HBV DNA only in infection. J Hepatol. 2009;51:798–809.
two, but the load was too low to be quantified. This is in 14 Hoofnagle JH, Seefe LB, Bales ZB, Zimmerman HJ. Type B hepatitis
after transfusion with blood containing antibody to hepatitis B core
agreement with previous studies that have shown that OBI antigen. N Engl J Med. 1978;298:1379–1383.
cases are associated with low HBV loads (<200 IU/ml) 13 15 Mosley JW, Stevens CE, Aach RD, Hollinger FB, Mimms LT,
and nucleic acid detection requires an assay with highest Solomon LR, et al. Donor screening for antibody to hepatitis B core
antigen and hepatitis B virus infection in transfusion recipients.
sensitivity and specificity with lower limit of detection of Transfusion. 1995;35(1):5–12.
<10 IU/ml.23 High viral loads in the absence of HBsAg 16 Allain JP. On behalf of the ISBT TTI working party “HBV safety”
study-group. Characterization of “occult” HBV yield cases identified
however have been reported in HIV co-infected individ- by NAT (ID or small pool) or anti-HBc screening. Available from:
uals from South Africa.24 http://www.isbtweb.org/files/documentation/ISBT-HBV-5
17 Chaudhuri V, Nanu A, Panda SK, Chand P. Evaluation of serologic
In Summary the incidence of OBI and WP infections screening of blood donors in India reveals a lack of correlation
was found to be low at 1 in 6503 and 1 in 24214 donations, between anti-HBc titer and PCR amplified HBV DNA. Transfusion.
2003;43:1442–1448.
respectively. The use of a very sensitive HBsAg assay
18 Panigrahi R, Biswas A, Datta S, Banerjee A, Chandra PK¸ Mahapatra 22 Yuen MF, Wong DKH, Lee CK, Tanaka Y, Allain JP, Fung J, et al.
PK, et al. Anti-hepatitis B core antigen testing with detection and Transmissibility of hepatitis B virus (HBV) infection through blood
characterization of occult hepatitis B virus by an in-house nucleic transfusion from blood donors with occult HBV infection. Clin Infect
acid testing among blood donors in Behrampur, Ganjam, Orissa in Dis. 2011;52:624–632.
southeastern India: implications for transfusion. Virol J. 2010;7:204–210. 23 Hollinger FB, Sood G. Occult hepatitis B virus infection: a covert
19 Bhattacharya P, Chandra PK, Datta S, Banerjee A¸ Chakraborty operation. J Viral Hepat. 2010;17:1–15.
S, Rajendran K, et al. Significant increase in HBV, HCV, HIV and 24 Bell TG, Makondo E, Martinson NA, Kramvis A. Hepatitis B virus
syphilis infections among blood donors in West Bengal, Eastern India infection in human immunodeficiency virus infected Southern
2004-2005: exploratory screening reveals high frequency of occult African adults: occult or overt - that is the question. Plos One.
HBV infection. World J Gastroenterol. 2007;13:3730–3733. 2012;7(10):e45750.
20 Hollinger FB. Hepatitis B virus infection and transfusion medicine: 25 Makroo RN, Chowdhry M, Bhatia A, Arora B, Rosamma NL.
science and the occult. Transfusion. 2008;48:1001–1026. Hepatitis B core antibody testing in Indian blood donors: a double-
21 Yang MH, Li L, Hung YS, Hung CH, Allain JP, Lin KS, et al. The edged sword! Asian J Transfus Sci. 2012;6(1):10–13.
efficacy of individual-donation and minipool testing to detect low-
level hepatitis B virus DNA in Taiwan. Transfusion. 2010;50:65–74.